Speaker(s): 

Pragya Dhaubhadel, MD, Staff Member, Geisinger - has nothing to disclose.

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

1.  Analyze current treatment for HS

2. Discuss the risks and benefits of extended intravenous ertapenam therapy for HS from ID lens

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Stanley Martin, MD; Julie Gombert, RN; Bradley Lauver, PharmD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant.